WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture Accessibility StatementSkip Navigation SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. The company reported a 16.7% increase in revenue, an IFRS gross pr ...